Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

PURPOSE: Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. Venetoclax efficacy in RRMM may be potentiated through combination with agents including bortezomib, dexamethasone, and daratumumab....

Descripción completa

Detalles Bibliográficos
Autores principales: Bahlis, Nizar J., Baz, Rachid, Harrison, Simon J., Quach, Hang, Ho, Shir-Jing, Vangsted, Annette Juul, Plesner, Torben, Moreau, Philippe, Gibbs, Simon D., Coppola, Sheryl, Yang, Xiaoqing, Al Masud, Abdullah, Ross, Jeremy A., Bueno, Orlando, Kaufman, Jonathan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577687/
https://www.ncbi.nlm.nih.gov/pubmed/34388020
http://dx.doi.org/10.1200/JCO.21.00443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577687/
https://www.ncbi.nlm.nih.gov/pubmed/34388020
http://dx.doi.org/10.1200/JCO.21.00443

Ejemplares similares